SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization ...

Carcinoid syndrome is a rare condition that occurs in patients with gastrointestinal tumors. These patients secrete an excessive amount of serotonin, which can lead to symptoms like frequent diarrhea, ...

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) ...

Xermelo’s (telotristat ethyl) dosage for carcinoid syndrome diarrhea is typically 250 milligrams (mg) three times per day. Your dosing may vary based on your symptoms and other medications you’re ...

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has begun its pivotal Phase 3 trial of Paltusotine in adults with carcinoid syndrome, dubbed CAREFNDR. Carcinoid syndrome affects about 20% of ...

As Crinetics prepares to make a tilt for FDA approval in a rare growth disorder later this year, a topline readout from a phase 2 study suggests the same drug also has the potential to treat symptoms ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSONIFY™ ...

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) ...

PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome.

Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent ...